Shots:

• Selecta to receive up front and ~$1.124B upon the achievement of development or commercial milestones or Takeda’s election continue its activities at specified development stages. Selecta is also eligible to receive royalties on future commercial sales
• The collaboration will utilize Selecta’s ImmTOR platform that accelerates transgene expression and addresses AAV vector immunogenicity to deliver transformative therapies for two indications
• ImmTOR has the potential to amplify the efficacy of biologic therapies- including redosing of gene therapies- restore the body’s natural self-tolerance in autoimmune diseases & can induce tolerance to highly immunogenic proteins

| Ref: Selecta | Image: Takeda